First-in-human study of teclistamab for relapsed/refractory Multiple Myeloma

Niels W. C. J. van de Donk, Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands, present in this MEDtalk, the result of first-in human study of teclistamab – a bispecific immunoglobulin G4 antibody that binds to both BCMA and CD3 to redirect CD3+ T cells to BCMA-expressing Multiple Myeloma cells